期刊
JOURNAL OF CONTROLLED RELEASE
卷 348, 期 -, 页码 357-369出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2022.05.033
关键词
Lipid nanoparticles; Genome editing; Innate immunity; Adjuvant delivery; Mitochondrial delivery; MITO-porter
资金
- Min-istry of Education, Culture, Sports, Science and Technology [19H01170, 20H04523, 20H0337301, 18K19888, 18K19889, 17H05052]
- Ministry of Education, Culture, Sports, Science and Technology
- Japanese Government (MEXT)
- Japan Science and Technology Agency (JST) [JPMJFR203X]
The recent progress in drug delivery systems has led to a new era in understanding the molecular mechanisms of cancer survival. This review summarizes new cancer strategies based on these delivery systems, including improving cancer immunotherapy, utilizing genome editing for therapeutic cargoes, and targeting cancer cell mitochondria through membrane fusion.
The recent rapid progress in the area of drug delivery systems (DDS) has opened a new era in medicine with a strong linkage to understanding the molecular mechanisms associated with cancer survival. In this review, we summarize new cancer strategies that have recently been developed based on our DDS technology. Cancer immunotherapy will be improved based on the concept of the cancer immunity cycle, which focuses on dynamic interactions between various types of cancer and immune cells in our body. The new technology of genome editing will also be discussed with reference to how these new DDS technologies can be used to introduce therapeutic cargoes into our body. Lastly, a new organelle, mitochondria will be the focus of creating a new cancer treatment strategy by a MITO-Porter which can deliver macromolecules directly to mitochondria of cancer cells via a membrane fusion approach and the impact of controlled intracellular trafficking will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据